Measuring Duchenne Where It Matters: Contractile Function in Human Engineered Muscle
September 7 is World Duchenne Awareness Day. This year's global theme, "Access changes lives," moves the conversation from awareness to action: access to diagnosis, access to care, and access to effective therapies. For preclinical researchers, one part of that chain is the quality of the human data that informs which candidates advance.
At Curi Bio, we build functional Duchenne muscular dystrophy (DMD) models on human iPSC-derived engineered muscle tissues (EMTs). Our platforms measure what muscle is supposed to do: generate force, sustain repeated contraction, and recover.
Disease-Relevant Human Muscle Biology
Reliable disease modeling starts with reliable biology.
Isogenic control and dystrophin-null myoblasts. iPSC-derived skeletal muscle myoblasts ship as matched pairs, so contractile differences track the dystrophin genotype rather than donor background.
Functional 3D tissues. Myoblasts assemble into 3D EMTs that couple to flexible posts and remain functional for more than a month in culture. Long-lived tissues let teams design both acute dosing studies and longitudinal experiments that follow phenotype emergence during maturation.
Quantitative, repeated-measures readouts. Mantarray™ records label-free contractile force from 24 tissues at once with per-well stimulation protocols, Nautilai™ adds optical calcium and voltage imaging, and Pulse™ analytics extract force, kinetics, and dose-dependent shifts from every waveform. Non-destructive measurement means the same tissue reports before and after treatment.
Click to view larger.
What Researchers Have Published Using These Tissues
The strongest case for a model comes from the groups using it.
Dystrophin-null tissues stratify from isogenic controls. Smith et al. (University of Washington) characterized CRISPR-edited dystrophin-null EMTs alongside isogenic controls on Mantarray, reporting the force, force-frequency, and cross-sectional area differences described above.
Epigenetic therapy rescues contractile deficits. Barrett et al. (University of Washington) reported force deficits, relaxation delays, and calcium and mitochondrial abnormalities in dystrophin-deficient EMTs, then showed that the HDAC inhibitor Trichostatin A reversed the contractile deficits in a dose-dependent manner.
Exon skipping produces measurable functional recovery. Entrada Therapeutics used the 3D engineered skeletal muscle system to connect exon skipping and dystrophin protein restoration to functional improvement in a human DMD cell model..
Patient-specific gene therapy candidates get a human functional test. Cure Rare Disease partnered with Curi Bio to evaluate a CRISPR-based therapy for patients with exon 1 deletions on cardiac and skeletal muscle EMTs, testing the construct against the patient's own cells before advancing it.
Disease stratification holds up as a screening readout. Our own team, led by Luttrell with Lih, Gray, Kharoufeh, Berry, Worthen, Luerman, and Geisse, showed that Mantarray separates DMD and isogenic control tissues across multiple contractility metrics, including force and fatigability, and that tissue longevity supports both acute and maturation-dependent study designs.
From Awareness to Access
Better human models will not close the access gap by themselves. Access depends on diagnosis,, infrastructure, and advocacy that the Duchenne community has built over decades. What functional human models can do is sharpen the decisions upstream of the clinic: rank candidates on the functional endpoint predictive of patient outcomes, and carry stronger evidence into trial design.
To the families, clinicians, advocates, and researchers driving this field: thank you for the work that makes these models worth building.
Contact us to learn more about how Curi Bio's EMT platforms can generate decision-driving functional data for your DMD program.